Huons (A243070) Stock Overview
Provides medical solutions for human health in Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
A243070 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Huons Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩27,700.00 |
| 52 Week High | ₩32,200.00 |
| 52 Week Low | ₩23,100.00 |
| Beta | 0.040 |
| 1 Month Change | 1.28% |
| 3 Month Change | -4.32% |
| 1 Year Change | 11.02% |
| 3 Year Change | -7.20% |
| 5 Year Change | -45.20% |
| Change since IPO | -45.53% |
Recent News & Updates
Recent updates
Huons Co., Ltd.'s (KOSDAQ:243070) Shares Bounce 26% But Its Business Still Trails The Market
Jan 08
Here's Why Huons (KOSDAQ:243070) Can Manage Its Debt Responsibly
Apr 20We Think That There Are Issues Underlying Huons' (KOSDAQ:243070) Earnings
Mar 17Here's Why We Think Huons (KOSDAQ:243070) Is Well Worth Watching
Mar 12Is Huons Co., Ltd.'s (KOSDAQ:243070) Recent Performance Tethered To Its Attractive Financial Prospects?
Feb 21What Type Of Shareholders Own The Most Number of Huons Co., Ltd. (KOSDAQ:243070) Shares?
Feb 02Could Huons Co., Ltd. (KOSDAQ:243070) Have The Makings Of Another Dividend Aristocrat?
Jan 12Should You Buy Huons Co., Ltd. (KOSDAQ:243070) For Its Upcoming Dividend?
Dec 25
Update: Huons (KOSDAQ:243070) Stock Gained 28% In The Last Year
Dec 08Is Huons Co., Ltd.'s (KOSDAQ:243070) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Nov 18Shareholder Returns
| A243070 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 1.1% | 0.6% | 0.3% |
| 1Y | 11.0% | 44.7% | 96.4% |
Return vs Industry: A243070 underperformed the KR Pharmaceuticals industry which returned 44.7% over the past year.
Return vs Market: A243070 underperformed the KR Market which returned 96.4% over the past year.
Price Volatility
| A243070 volatility | |
|---|---|
| A243070 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 2.8% |
Stable Share Price: A243070 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A243070's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | n/a | n/a | www.huons.com |
Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, anti-coagulant, antiviral, central nervous system, antibiotic, well-being, urogenital system, and other chemotherapeutic products; and injection products, such as anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic, antihistamine, circulatory system, respiratory system, adrenocortical hormone, enzyme, mineral, solvent, calcium, hemostatic, antidote, antibiotic, metabolic, hyaluronic acid, well-being, anticoagulant, and other tissue cell system products. It also provides eye drop and bio products, as well as medical devices.
Huons Co., Ltd. Fundamentals Summary
| A243070 fundamental statistics | |
|---|---|
| Market cap | ₩316.35b |
| Earnings (TTM) | ₩35.75b |
| Revenue (TTM) | ₩602.21b |
Is A243070 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A243070 income statement (TTM) | |
|---|---|
| Revenue | ₩602.21b |
| Cost of Revenue | ₩320.09b |
| Gross Profit | ₩282.11b |
| Other Expenses | ₩246.36b |
| Earnings | ₩35.75b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.07k |
| Gross Margin | 46.85% |
| Net Profit Margin | 5.94% |
| Debt/Equity Ratio | 41.8% |
How did A243070 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 10:47 |
| End of Day Share Price | 2026/02/03 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Huons Co., Ltd. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyoseob Shin | Bookook Securities Co. Ltd |
| Mi Hyun Kim | Eugene Investment & Securities Co Ltd. |
| Bong Jin Lee | Hanwha Investment & Securities Co., Ltd. |